Display options
Cite
Fonteneau G, Bony C, Goulabchand R, et al. Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients Affects Mesenchymal Stem Cell Function. Front Immunol. 2017;8:988doi: 10.3389/fimmu.2017.00988.
Fonteneau, G., Bony, C., Goulabchand, R., Maria, A. T. J., Le Quellec, A., Rivière, S., Jorgensen, C., Guilpain, P., & Noël, D. (2017). Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients Affects Mesenchymal Stem Cell Function. Frontiers in immunology, 8988. https://doi.org/10.3389/fimmu.2017.00988
Fonteneau, Guillaume, et al. "Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients Affects Mesenchymal Stem Cell Function." Frontiers in immunology vol. 8 (2017): 988. doi: https://doi.org/10.3389/fimmu.2017.00988
Fonteneau G, Bony C, Goulabchand R, Maria ATJ, Le Quellec A, Rivière S, Jorgensen C, Guilpain P, Noël D. Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients Affects Mesenchymal Stem Cell Function. Front Immunol. 2017 Sep 01;8:988. doi: 10.3389/fimmu.2017.00988. eCollection 2017. PMID: 28919892; PMCID: PMC5585199.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2017 Sep 01;8:988. doi: 10.3389/fimmu.2017.00988. eCollection 2017.

Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients Affects Mesenchymal Stem Cell Function.

Frontiers in immunology

Guillaume Fonteneau, Claire Bony, Radjiv Goulabchand, Alexandre T J Maria, Alain Le Quellec, Sophie Rivière, Christian Jorgensen, Philippe Guilpain, Danièle Noël

Affiliations

  1. IRMB, INSERM, Montpellier University, Montpellier, France.
  2. Department of Internal Medicine, Multiorganic Diseases, Saint-Eloi Hospital, Montpellier, France.
  3. Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie Hospital, Montpellier, France.

PMID: 28919892 PMCID: PMC5585199 DOI: 10.3389/fimmu.2017.00988

Abstract

OBJECTIVES: Properties of mesenchymal stromal/stem cells (MSCs) from systemic sclerosis (SSc) patients have been reported to be altered. MSC-based therapy may therefore rely on the use of allogeneic MSCs from healthy subjects. Here, we investigated whether heterologous MSCs could exhibit altered properties following exposure to oxidative environment of SSc sera.

METHODS: Human bone marrow-derived MSCs were cultured in the presence of various sera: control human serum AB (SAB), SAB with HOCl-induced AOPPs at 400 or 1,000 µmol/L (SAB

RESULTS: In the presence of oxidative environment of PS, MSCs retained their proliferative potential and survived for at least the first 3 days of exposure, while the number of senescent MSCs increased at day 6 and apoptosis rate at day 10. Exposure to PS enhanced the antioxidant capacity of MSCs, notably the expression of SOD2 antioxidant gene. By contrast, the osteoblastic/adipogenic potential of MSCs was increased, whereas their immunosuppressive function was slightly reduced.

DISCUSSION: Although some functional properties of MSCs were affected upon culture with PS, evidence from preclinical studies and the present one suggested that MSCs can adapt to the oxidative environment and exert their therapeutic effect.

Keywords: advanced oxidation protein product; cell therapy; mesenchymal stem cells; oxidative stress; systemic sclerosis

References

  1. Int J Med Sci. 2014 Sep 13;11(11):1201-7 - PubMed
  2. Rheumatology (Oxford). 2007 Mar;46(3):403-8 - PubMed
  3. J Immunol. 2009 May 1;182(9):5855-64 - PubMed
  4. Nat Biotechnol. 2014 Mar;32(3):252-60 - PubMed
  5. J Biol Regul Homeost Agents. 2013 Jan-Mar;27(1):211-24 - PubMed
  6. Arthritis Rheumatol. 2016 Apr;68(4):1013-25 - PubMed
  7. J Biol Chem. 2008 May 30;283(22):15319-27 - PubMed
  8. J Autoimmun. 2016 Jun;70:31-9 - PubMed
  9. Stem Cell Res Ther. 2011 Mar 18;2(2):14 - PubMed
  10. Arthritis Res Ther. 2014 Sep 24;16(5):442 - PubMed
  11. Cell Mol Life Sci. 2014 Nov;71(21):4207-19 - PubMed
  12. Oxid Med Cell Longev. 2016;2016:2989076 - PubMed
  13. BMJ Open. 2013 Jan 07;3(1):null - PubMed
  14. Clin Exp Immunol. 2013 Aug;173(2):195-206 - PubMed
  15. Ann Rheum Dis. 2007 Sep;66(9):1202-9 - PubMed
  16. Cell Transplant. 2017 May 9;26(5):841-854 - PubMed
  17. Cell Transplant. 2014;23(9):1045-59 - PubMed
  18. Angiogenesis. 2013 Jul;16(3):595-607 - PubMed
  19. Stem Cell Res Ther. 2015 Aug 08;6:140 - PubMed
  20. Autoimmun Rev. 2014 Feb;13(2):151-6 - PubMed
  21. Ann Rheum Dis. 2008 Apr;67(4):443-9 - PubMed
  22. Stem Cells Dev. 2013 Mar 15;22(6):878-88 - PubMed
  23. Clin Rev Allergy Immunol. 2017 Apr;52(2):234-259 - PubMed
  24. Leukemia. 2008 May;22(5):1062-4 - PubMed
  25. Cell Transplant. 2013;22(5):779-95 - PubMed
  26. Stem Cells Dev. 2012 Jul 20;21(11):1877-86 - PubMed
  27. Stem Cell Res Ther. 2017 Feb 7;8(1):23 - PubMed
  28. Arthritis Res Ther. 2005;7(6):R1304-15 - PubMed

Publication Types